Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution

[Guest guest]

Clin Transplant. 2008 Dec 9. [Epub ahead of print]

Reactivation of hepatitis B two years after rituximab therapy in a renal

transplant patient with recurrent focal segmental glomerulosclerosis: a note of

caution.

Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA.

Transplantationsambulanz, KfH Nierenzentrum, furt, Germany.

Gossmann J, Scheuermann E-H, Kachel H-G, Geiger H, Hauser IA. Reactivation of

hepatitis B two years after rituximab therapy in a renal transplant patient with

recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant

2008 DOI: 10.1111/j.1399-0012.2008.00936.x © 2008 Wiley Periodicals, Inc.

Abstract:

We report on the reactivation of hepatitis B in a renal transplant patient who

had been treated with rituximab for recurrent focal segmental glomerulosclerosis

two and a half yr previously. He lost his anti-hepatitis B surface antigens and

anti-hepatitis B core antigen antibodies and developed hepatitis B virus

(HBV)-DNA positive hepatitis. Hepatitis C, which had been successfully treated

by alpha interferon 10 yr before, remained quiescent. We suggest regular

controls of HBV-DNA, anti-HBV antibodies and transaminases for prolonged periods

in patients with status post-hepatitis B treated with rituximab. Prophylactic

therapy with lamivudine and/or hepatitis B hyperimmune globulin may be

considered in patients with a decrease in anti-HBV antibodies.

PMID: 19077081 [PubMed - as supplied by publisher]

[Guest guest]

Clin Transplant. 2008 Dec 9. [Epub ahead of print]

Reactivation of hepatitis B two years after rituximab therapy in a renal

transplant patient with recurrent focal segmental glomerulosclerosis: a note of

caution.

Gossmann J, Scheuermann EH, Kachel HG, Geiger H, Hauser IA.

Transplantationsambulanz, KfH Nierenzentrum, furt, Germany.

Gossmann J, Scheuermann E-H, Kachel H-G, Geiger H, Hauser IA. Reactivation of

hepatitis B two years after rituximab therapy in a renal transplant patient with

recurrent focal segmental glomerulosclerosis: a note of caution. Clin Transplant

2008 DOI: 10.1111/j.1399-0012.2008.00936.x © 2008 Wiley Periodicals, Inc.

Abstract:

We report on the reactivation of hepatitis B in a renal transplant patient who

had been treated with rituximab for recurrent focal segmental glomerulosclerosis

two and a half yr previously. He lost his anti-hepatitis B surface antigens and

anti-hepatitis B core antigen antibodies and developed hepatitis B virus

(HBV)-DNA positive hepatitis. Hepatitis C, which had been successfully treated

by alpha interferon 10 yr before, remained quiescent. We suggest regular

controls of HBV-DNA, anti-HBV antibodies and transaminases for prolonged periods

in patients with status post-hepatitis B treated with rituximab. Prophylactic

therapy with lamivudine and/or hepatitis B hyperimmune globulin may be

considered in patients with a decrease in anti-HBV antibodies.

PMID: 19077081 [PubMed - as supplied by publisher]